 All patients will return for assessment of efficacy and safety at Weeks 4, 8, and 12. The maximum study duration for a patient is 14 weeks. Patients who are not anaemic at Week 12 will be invited to continue to participate in a maintenance study FER-IBD-07-MAIN, i.e. a study of FERINJECT versus placebo to determine if the treatment of iron deficiency can prevent the recurrence of anaemia. 